Table 1.
Summary of clinical trials investigating the outcome of different KRAS mutation subtypes.
| Study | Pts | KRAS status | Treatment | Endpoint | KRAS status | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jia et al. (49) | 170 | WT | G12C | G12V | G12D | Rare | First-line chemotherapy | WT | G12C | G12V | G12D | Rare | |||
| 59% (100) | 14% (23) | 11% (18) | 5% (9) | 11% (20) | ORR (%) | 19.0 | 26.1 | 22.2 | 11.1 | 20.0 | |||||
| PFS (months) | 6.4 | 4.4 | 2.9 | 7.0 | 4.7 | ||||||||||
| DCR (%) | 86 | 78.3 | 55.6 | 66.7 | 60 | ||||||||||
| Cserepes et al. (50) | 494 | WT | G12C | G12V | G12D | Rare | COD13 MUT | First-line chemotherapy | WT | G12C | G12V | G12D | Rare | COD13 MUT | |
| 68% (338) | 12% (61) | 6% (29) | 6% (27) | 4% (19) | 4% (20) | PFS (days) | 211 | 191 | 233 | 150 | 198 | 157 | |||
| OS (days) | 479 | 561 | 470 | 325 | 559 | 330 | |||||||||
| Sun et al. (51) | 304 | WT | G12C | G12V | G12D | Rare | First-line chemotherapy | WT | G12C | G12V | G12D | Rare | |||
| 87% (265) | 3% (9) | 3% (10) | 4% (13) | 3% (7) | OS (months) | 15 | 7.7 | 9.6 | 8.1 | 5.5 | |||||
| Ghimessy et al. (52) | WT | G12C | G12V | G12D | Rare | BEV/CHT | WT | G12/13X | G12D | ||||||
| 213 | 61% (130) | 16% (35) | 10% (20) | 9% (19) | 4% (9) | PFS (months) | 11.70 | 8.27 | 3.70 | ||||||
| OS (months) | 21.0 | 16.1 | 7.2 | ||||||||||||
| G12C | Sotorasib | G12C | |||||||||||||
| Skoulidis et al. (53) | 124 | 124 | ORR (%) | 37.1 | |||||||||||
| PFS (months) | 6.8 | ||||||||||||||
| Jeanson et al. (54) | G12A | G12C | G12D | G12V | G13C | ICIs | G12A | G12C | G12D | G12V | G13C | ||||
| 144 | 10% (15) | 48% (69) | 17% (25) | 17% (24) | 8% (11) | ORR (%) | 13.3 | 18.5 | 20.0 | 18.2 | 18.2 | ||||
| PFS (months) | 2.66 | 3.09 | 3.91 | 2.69 | 4.60 | ||||||||||
| Jänne et al. (55) | G12C/V | Non-G12C/V | Selumetinib + docetaxel | G12C/V | Non-G12C/V | ||||||||||
| 83 | 57% (47) | 43% (36) | PFS (months) | 5.7 | 4.9 | ||||||||||
| OS (months) | 9.6 | 8.6 | |||||||||||||
| Placebo + docetaxel | PFS (months) | 1.4 | 2.6 | ||||||||||||
| OS (months) | 4.4 | 7.1 | |||||||||||||
KRAS, kirsten rat sarcoma viral oncogene homolog; Pts, patients; ORR, objective response rate; PFS, progression-free survival; DCR, disease control rate; OS, overall survival; BEV, bevacizumab; CHT, chemotherapy; ICIs, immune checkpoint inhibitors.